Arcus Biosciences (RCUS) Cash & Current Investments (2017 - 2026)

Arcus Biosciences' Cash & Current Investments history runs 10 years deep, the most recent figure standing at $822.0 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 17.55% year-over-year to $822.0 million in Q1 2026; TTM through Mar 2026 was $822.0 million, a 17.55% decrease from a year earlier, with the FY2025 full-year figure at $981.0 million, changed 0.31% from the prior year.
• Cash & Current Investments retreated to $822.0 million in Q1 2026 per RCUS's latest filing, from $981.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.2 billion in Q1 2022 and bottomed at $759.0 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $978.0 million (2024), against an average of $968.2 million.
• Across the five-year window, Cash & Current Investments surged 102.2% in 2022 and dropped 24.78% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $1.0 billion in 2022, then decreased by 24.78% to $759.0 million in 2023, then rose by 28.85% to $978.0 million in 2024, then grew by 0.31% to $981.0 million in 2025, then declined by 16.21% to $822.0 million in 2026.
• Per Business Quant, the three latest RCUS Cash & Current Investments figures stand at $822.0 million (Q1 2026), $981.0 million (Q4 2025), and $831.0 million (Q3 2025).